The International Human Epigenome Consortium (IHEC) coordinates the generation of a catalog of high-resolution reference epigenomes of major primary human cell types. The studies now presented (see the Cell Press IHEC web portal at http://www.cell.com/consortium/IHEC) highlight the coordinated achievements of IHEC teams to gather and interpret comprehensive epigenomic datasets to gain insights in the epigenetic control of cell states relevant for human health and disease.
One of the great mysteries in developmental biology is how the same genome can be read by cellular machinery to generate the plethora of different cell types required for eukaryotic life. As appreciation grew for the central roles of transcriptional and epigenetic mechanisms in specification of cellular fates and functions, researchers around the world encouraged scientific funding agencies to develop an organized and standardized effort to exploit epigenomic assays to shed additional light on this process (Beck et al., 1999; Jones and Martienssen, 2005 In March 2009, leading scientists and international health research funding agency representatives were invited to a meeting in Bethesda, Maryland (US), to gauge the level of interest in an international epigenomics project and to identify potential areas of focus. This meeting, and a subsequent conference in January 2010 in Paris (France) ultimately led to the creation of the International Human Epigenome Consortium (IHEC).
The primary goals of IHEC are to coordinate the production of reference maps of human epigenomes for key cellular states relevant to health and diseases, to facilitate rapid distribution of the data to the research community, and to accelerate translation of this new knowledge to improve human health. A critical component of IHEC is to coordinate the development of common bioinformatics standards, data models and analytical tools to organize, integrate and display the epigenomic data generated.
IHEC members all contribute to these primary goals, but they also have individual complementary goals such as developing new and improved ways to monitor or manipulate the epigenome, discovering new epigenomic mechanisms, training the next generation of epigenome researchers, exploring epigenomic features associated with disease states, and translating epigenomic discoveries into improvements to human health. This is in keeping with the larger overarching vision of IHEC, which is to help address fundamental questions in how the genome and environment interact during development and aging, and how the epigenome influences health and disease.
There are many strengths to a consortium model, bringing together research expertise and knowledge from across the world. These include the ability to implement and monitor high-quality data and assay standards and to maximize coverage of human cells and tissues while avoiding unnecessary duplication. Additionally, this model helps harmonize data collection, management, and analysis, to facilitate sharing and retrieval across countries and provides open access to data and results. IHEC provides a mechanism to facilitate communication among members and provides a forum for coordination with the objective of maximizing efficiency among researchers working to understand, treat, and prevent diseases.
Current full members of IHEC include: AMED CREST/IHEC Team Japan; DLR-PT for BMBF German Epigenome Programme DEEP; CIHR Canadian Epigenetics Environment, and Health Research Consortium (CEEHRC); European Union FP7 BLUEPRINT Project; Hong Kong Epigenomics Project; KNIH Korea Epigenome Project; NHGRI ENCODE; the NIH Roadmap Epigenomics Program; and the Singapore Epigenome Project (http://ihec-epigenomes.org/). In the subsequent sections, we overview experimental and computational tools developed by IHEC members and highlight key findings from a collection of recent publications from IHEC members.
Indentifying Heterogeneity in Epigenomic Measurements
Cellular and allelic heterogeneity provides a significant challenge in the interpretation of epigenomic signatures that are typically derived from heterogeneous populations of millions of individual cells. To address this challenge, we have developed a series of molecular and computational approaches to deconvolute epigenomic signatures from heterogeneous populations. Three independent strategies are presented to explore the heterogeneity at bivalent domains, a ''poised
